Clinical Trial Update: Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers. [Phase 2]

View source ↗

Summary

Phase 2 trial update on immunogenicity and safety of the meningococcal vaccine GSK134612 given in 1 or 2 doses to healthy 9–12 month old toddlers; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• GSK134612 (Meningococcal vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2018-09-14